ImmunityBio CAO RSU vesting, tax share withholding

ImmunityBio, Inc. Chief Accounting Officer Regan J. Lauer reported vesting of 4,065 restricted stock units (RSUs) on February 22, 2026.

Rhea-AI Filing Summary

ImmunityBio, Inc. Chief Accounting Officer Regan J. Lauer reported vesting of 4,065 restricted stock units (RSUs) on February 22, 2026. Each RSU converts into one share of common stock, so 4,065 shares were acquired at a stated price of $0.00 per share.

To satisfy tax obligations from this vesting, 1,673 common shares were disposed of at $8.70 per share through share withholding, rather than an open-market sale. After these transactions, Lauer directly owns 115,875 shares of ImmunityBio common stock.

Insider Trade Summary

4,065 shares exercised/converted

Exercise 3 txns

Insider LAUER REGAN J

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	4,065	$0.00	$0.00
Exercise	Common Stock	4,065	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,673	$8.70	$15K

Holdings After Transaction: Restricted Stock Units — 4,065 contracts (Direct); Common Stock — 115,875 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
2. F2. On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.
3. F3. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ImmunityBio (IBRX) report for Regan J. Lauer?

ImmunityBio reported that Chief Accounting Officer Regan J. Lauer had 4,065 restricted stock units vest into common shares, then 1,673 of those shares were withheld to cover tax obligations, leaving Lauer with direct ownership of 115,875 ImmunityBio common shares.

How many ImmunityBio (IBRX) shares did the CAO acquire and dispose of?

Regan J. Lauer acquired 4,065 shares of ImmunityBio common stock via RSU vesting and disposed of 1,673 shares through tax-withholding at a price of $8.70 per share, ending with direct ownership of 115,875 common shares after the reported Form 4 transactions.

Were the ImmunityBio (IBRX) insider transactions open-market buys or sales?

The transactions were not open-market trades. Lauer’s 4,065 shares were acquired through RSU vesting (code M), and 1,673 shares were disposed of via share withholding (code F) to pay tax liabilities associated with the vesting, rather than through open-market purchases or sales.

What do the restricted stock units (RSUs) represent for ImmunityBio (IBRX)?

Each ImmunityBio restricted stock unit represents a contingent right to receive one share of ImmunityBio common stock. When the RSUs vest, as they did on February 22, 2026 for 4,065 units, they automatically convert into an equal number of common shares for the reporting person.

What is the vesting schedule for the ImmunityBio (IBRX) RSU award?

The RSU award vests over three years from a February 22, 2024 vesting commencement date. 33.33% vests in equal annual installments on each of the first and second anniversaries, and 33.34% vests on the third anniversary, subject to continued service as a Service Provider.

How many ImmunityBio (IBRX) shares does the CAO own after these Form 4 transactions?

Following the RSU vesting and related tax-withholding disposition, Regan J. Lauer directly owns 115,875 shares of ImmunityBio common stock. This figure reflects the net position after acquiring 4,065 shares from RSU conversion and disposing of 1,673 shares to satisfy associated tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 08:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAUER REGAN J

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/22/2026		M		4,065	A	$0	117,548	D
Common Stock	02/22/2026		F		1,673	D	$8.7(2)	115,875	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/22/2026		M			4,065	(3)	(3)	Common Stock	4,065	$0	4,065	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

2. On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

3. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.